Significance of mouse xenograft tumor model using patient-derived cancer organoids for clinical drug development
These findings suggest that <i>in vivo</i> studies using PDCO xenograft tumor models may be more suitable than conventional mouse tumor models for determining the clinical development of drugs.
Authors
- Hideaki Tahara (ORCID: https://orcid.org/0000-0002-1735-5372)
- Hisataka Ogawa (ORCID: https://orcid.org/0000-0002-9317-5007)
- Hiroshi Wada (ORCID: https://orcid.org/0000-0001-9538-1624)
- Masayoshi Yasui (ORCID: https://orcid.org/0000-0001-6391-3630)
- Shinichiro Hasegawa (ORCID: https://orcid.org/0000-0001-8117-8350)
- Keiichi Yoshida (ORCID: https://orcid.org/0000-0003-3152-6059)
Institutions
- Nitto (Japan) (JP)
- Osaka International Cancer Institute (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.3389/fonc.2025.1485886
- Citations
- 5
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 5.23